A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
| Autor: | J, Kaern, M, Baekelandt, C G, Tropé |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Ovarian Neoplasms Analysis of Variance Dose-Response Relationship Drug Maximum Tolerated Dose Paclitaxel Remission Induction Middle Aged Risk Assessment Disease-Free Survival Drug Administration Schedule Survival Rate Treatment Outcome Drug Resistance Neoplasm Humans Female Infusions Intravenous Aged Follow-Up Studies Platinum Probability |
| Zdroj: | European journal of gynaecological oncology. 23(5) |
| ISSN: | 0392-2936 |
| Popis: | In platinum-resistant ovarian cancer weekly paclitaxel has shown an equal efficiency and better toxicity profile compared to three-weekly paclitaxel in platinum-resistant ovarian cancer. We wanted to study response rate, response duration and toxicity in platinum-resistant tumors with emphasis on tumors also resistant to three-weekly paclitaxel.Fifty-seven patients with platinum-resistant disease, treated with weekly paclitaxel 80 mg/m2, 1-hour infusion, were evaluable for response and toxicity (Group A). Of these, 39 patients (Group B) had tumors resistant to paclitaxel as well.Overall response rate was 56% (12% CR, 44% PR, 19% SD, 25% PD) and 49% in group B: 5% CR, 44% PR, 23% SD, 28% PD. Median progression-free survival was 5.0 months and 4.0 months in group A and B, respectively. Median survival was 13.7 months in both groups. Toxicity was mild. Only two patients had grade 2 neutropenia and no neutropenic fever was recorded. No worsening in pre-existing neurotoxicity or hypersensitivity reactions was observed.Weekly administration of paclitaxel is associated with promising response rates in patients with platinum- and paclitaxel-resistant ovarian cancer. The treatment is well tolerated with non-cumulative hematologic and non-hematologic toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|